Bayer Selects InforSense for Next Generation Integrative Analytics Infrastructure
News Sep 16, 2005
InforSense Ltd has announced that Bayer Healthcare AG, a member of the Bayer Group has selected InforSense technology to enhance their drug discovery informatics infrastructure.
InforSense's workflow-based integrative analytics environment, InforSense KDE, will provide Bayer with a flexible rapid application development platform to optimize their drug discovery decision-making.
"To identify and optimize potential drug leads, Bayer's chemists need both rapid processing of large compound libraries via chemical cartridge technology coupled with easy access to best of breed proprietary and third party analytic tools and visualizations," said Dr. Alexander Hillisch, Head of Computational Chemistry at Bayer Healthcare AG.
"InforSense Open Discovery Workflow™ technology offers the appropriate environment for rapidly composing data and applications, including our in-house in silico ADMET tools, to optimize our high-throughput cheminformatics analysis."
"We are delighted that Bayer has chosen InforSense," commented Joseph F. Donahue, Chief Business Officer, InforSense.
"InforSense KDE will facilitate the composition, integration and deployment of a wide range of cheminformatics applications by giving Bayer's computational chemists access to their chosen set of tools via cutting-edge workflow technology."
Comments | 0 ADD COMMENT
Orphan Drugs and Rare Diseases Global Congress 2017 USA
Sep 12 - Sep 14, 2017